These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8437282)

  • 21. Activation by the protein-bound polysaccharide PSK (krestin) of cytotoxic lymphocytes that act on fresh autologous tumor cells and T24 human urinary bladder transitional carcinoma cell line in patients with urinary bladder cancer.
    Mizutani Y; Yoshida O
    J Urol; 1991 May; 145(5):1082-7. PubMed ID: 2016797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selection of treatment for muscle infiltrating transitional cell bladder cancer.
    Whitmore WF
    Arch Esp Urol; 1990; 43 Suppl 2():219-22. PubMed ID: 2096783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A bladder cancer multi-institutional experience with total cystectomy for muscle-invasive bladder cancer.
    Scher HI
    J Urol; 1994 Aug; 152(2 Pt 1):574-5. PubMed ID: 8015114
    [No Abstract]   [Full Text] [Related]  

  • 24. Invasive bladder cancer--where do we go from here?
    Waters WB
    J Urol; 1996 Jun; 155(6):1910-1. PubMed ID: 8618285
    [No Abstract]   [Full Text] [Related]  

  • 25. Doxorubicin hypogastric artery infusion combined with hyperthermia therapy for transitional cell carcinoma of the bladder.
    Jacobs SC; Maddison FE; Lawson RK
    Cancer Treat Rep; 1981; 65(9-10):891-3. PubMed ID: 7273025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternative therapies for bladder carcinoma.
    Marshall M; Price SE; Barnhouse DH; Powell JR
    Pa Med; 1987 May; 90(5):76-8. PubMed ID: 3587987
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of hyperthermia on bladder cancer.
    Hall RR; Schade RO; Swinney J
    Br Med J; 1974 Jun; 2(5919):593-4. PubMed ID: 4833966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acridine-orange flow cytometry of urinary bladder washings for the detection of transitional cell carcinoma of the bladder. The influence of prior local therapy.
    Têtu B; Katz RL; Kalter SP; von Eschenbach AC; Barlogie B
    Cancer; 1987 Oct; 60(8):1815-22. PubMed ID: 3652008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long term protection in bladder cancer following intralesional immunotherapy.
    Reichert DF; Lamm DL
    J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [pT1G3 bladder carcinoma: our experience].
    Dell'Orto P; Trinchieri A; D'Addezio F; Bernardini P; Mangiarotti B; Del Nero A; Pisani E
    Arch Ital Urol Androl; 1996 Feb; 68(1):9-11. PubMed ID: 8664927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation criteria: a protocol to study patterns of care and their effects in patients with transitional cell carcinoma of the bladder (protocol 1).
    Prout GR; Kopp J
    Prog Clin Biol Res; 1984; 162A():285-99. PubMed ID: 6483913
    [No Abstract]   [Full Text] [Related]  

  • 32. Bladder carcinoma treated by irradiation and surgery: interval report.
    Deweerd JH; Colby MY
    Trans Am Assoc Genitourin Surg; 1972; 64():74-8. PubMed ID: 4654525
    [No Abstract]   [Full Text] [Related]  

  • 33. Pathology of bladder cancer: assessment of the primary lesion and response to therapy.
    Reuter VE
    Prog Clin Biol Res; 1990; 353():45-56. PubMed ID: 2217426
    [No Abstract]   [Full Text] [Related]  

  • 34. Organ conservation in deeply invasive bladder cancer.
    Fair WR
    Prog Clin Biol Res; 1991; 370():119-26. PubMed ID: 1924440
    [No Abstract]   [Full Text] [Related]  

  • 35. Experimental models for therapeutic studies of transitional cell carcinoma.
    Gabriel U; Bolenz C; Michel MS
    Anticancer Res; 2007; 27(5A):3163-71. PubMed ID: 17970057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clonogenic growth of cells derived from bladder barbotage in patients with transitional cell carcinoma of the bladder: a preliminary report.
    Niell HB; Soloway MS; Nissenkorn I
    J Urol; 1982 Apr; 127(4):668-70. PubMed ID: 7069828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of murine transitional cell carcinoma with intralesional interleukin 2 and murine interferon gamma.
    Sosnowski JT; DeHaven JI; Riggs DR; Lamm DL
    J Urol; 1991 Oct; 146(4):1164-7. PubMed ID: 1910098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allium sativum (garlic) treatment for murine transitional cell carcinoma.
    Riggs DR; DeHaven JI; Lamm DL
    Cancer; 1997 May; 79(10):1987-94. PubMed ID: 9149027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A feasibility study for the non-invasive treatment of superficial bladder tumours with focused ultrasound.
    Watkin NA; Morris SB; Rivens IH; Woodhouse CR; ter Haar GR
    Br J Urol; 1996 Nov; 78(5):715-21. PubMed ID: 8976766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumoral local effect and metastatic risk of focused extracorporeal pyrotherapy on Dunning R-3327 tumors.
    Bataille N; Vallancien G; Chopin D
    Eur Urol; 1996; 29(1):72-7. PubMed ID: 8821695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.